FDA Approves New Combination Treatment Using Immunotherapy Before Surgery for Early-Stage NSCLC

[Miranda_GO2]

On March 4th, 2022, the Food and Drug Administration (FDA) approved Opdivo (nivolumab) for treatment before surgery in combination with platinum-based chemotherapy in patients with stage IB to IIIA non-small cell lung cancer (NSCLC). The approval was based on the results of the clinical trial CHECKMATE-816 which showed that patients who received Opdivo and chemotherapy before surgery went longer without recurrence following surgery and had a higher chance of the tumor responding to treatment.

Opdivo’s approval for patients who are eligible to receive surgery on their NSCLC marks the first approval for an immunotherapy in that setting and provides hope for better outcomes for many patients diagnosed with early-stage NSCLC.

Here is the link to read the FDA Press Release: fda.gov/drugs/resources-inf...

[Denzie Moderator Volunteer]

Groundbreaking! Research saving more lives all the time.

[Feelingblessed2013]

A bit late for me, but still great news for all those just starting this journey.

[hopejunkie]

This is indeed incredibly news!!! Do you know if there’s been any other agents (immunotherapy or not) FDA approved to treat early stage NSCLC neoadjuvantly (before surgery)?